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ABSTRACT To study the binding specificity of Src ho-
mology 3 (SH3) domains, we have screened a mouse embry-
onic expression library for peptide fragments that interact
with them. Several clones were identified that express frag-
ments of proteins which, through proline-rich binding sites,
exhibit differential binding specificity to various SH3 do-
mains. Src-SH3-specific binding uses a sequence of 7 aa of the
consensus RPLPXXP, in which the N-terminal arginine is
very important. The SH3 domains of the Src-related kinases
Fyn, Lyn, and Hck bind to this sequence with the same affinity
as that of the Src SH3. In contrast, a quite different proline-
rich sequence from the Btk protein kinase binds to the Fyn,
Lyn, and Hck SH3 domains, but not to the Src SH3. Specific
binding of the Abl SH3 requires a longer, more proline-rich
sequence but no arginine. One clone that binds to both Src and
Abl SH3 domains through a common site exhibits reversed
binding orientation, in that an arginine indispensable for
binding to all tested SH3 domains occurs at the C terminus.
Another clone contains overlapping yet distinct Src and Abl
SH3 binding sites. Binding to the SH3 domains is mediated by
a common PXXP amino acid sequence motif present on all
ligands, and specificity comes about from other interactions,
often ones involving arginine. The rules governing in vivo
usage of particular sites by particular SH3 domains are not
clear, but one binding orientation may be more specific than
another.
Protein-protein interactions are central events in cellular
signal transduction. These interactions are often mediated by
noncatalytic conserved domains, three of which are the Src
homology regions 2 and 3 (SH2 and SH3), first identified as
part of the Rous sarcoma viral oncogene product (1, 2), and
the plekstrin homology (PH) domain, more recently identified
by protein sequence alignments (3, 4). To date, the best
understood protein interactions are those mediated by the SH2
domains, which bind to phosphotyrosine residues on proteins
that have been primed for signaling through phosphorylation.
The function of SH3 domains is less clear. In relation to the
oncogenic potential of protein-tyrosine kinases, these domains
play an inhibitory role because mutation or deletion of them
activates the transforming potential of c-Src and c-Abl pro-
tooncoproteins (5-7). The first clue to the function of SH3
domains was obtained by the cloning of fragments of two
protein ligands for the Abl SH3: 3BP1 and 3BP2 (8). In these
proteins, proline-rich peptides only 10 aa long serve as targets
of SH3 binding (9). Since then, a number of interactions
between SH3 domains and proline-rich ligands have been
described, showing that SH3 domains are involved in epider-
mal growth factor receptor signaling (10), cellular localization
of cytoplasmic proteins (11), upregulation of the GTPase
activity of dynamin (12), and activation of phosphatidylinositol
3-kinase in response to IgM crosslinking (13).
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From these and other reports it is now clear that interactions
between SH3s and their ligands occur through proline-rich
sites. It is less clear, however, how the specificity of interaction
is achieved. In this study we report the isolation of peptide
fragments from proteins that exhibit differential binding spec-
ificity to various SH3s. Specificity of interaction is mediated by
unique sequences that interact with binding pockets found on
the surface of SH3 domains. Our data correlate well with
recent reports that identify specific artificial ligands for dif-
ferent SH3 domains from chemically synthesized and phage
display libraries (14-16) and suggest that these ligands do
occur in vivo.
MATERIALS AND METHODS
Library Screening. A 16-day mouse embryo cDNA expres-
sion library (Novagen) was screened for SH3-binding proteins
according to the manufacturer's protocols and as previously
described (8). Biotinylated glutathione S-transferase (GST)-
SH3 fusion proteins of c-Abl, c-Src, c-Crk, and neuronal Src
(n-Src) were used as probes to screen the library. Positive
phage plaques were purified and recombinant phage were
converted into plasmids through Cre-mediated excision from
AEXlox by plating phage with the appropriate host. Recom-
binant plasmids (pEXlox) were then transformed into com-
petent bacteria (Novagen) that permitted expression of the
cloned cDNAs as fusion proteins of gene 10 of phage T7.
Filter Binding Assay. Bacteria cell lysates were prepared as
described (9). Proteins were fractionated by electrophoresis
through polyacrylamide gels and transferred to nitrocellulose
filters that were processed as described (9). Immunoblotting
with affinity-purified polyclonal antibody to GST was per-
formed as described (9).
Subcloning. Construct GST-lOa (see Fig. 2D) contains a
92-codon fragment of the library clone derived by oligonucle-
otide-directed polymerase chain reaction (PCR) and sub-
cloned in frame into the pGEX2T prokaryotic expression
vector. Primers for the PCR contained 24 bp of coding
sequence, a BamHI site at the 5' end of the sense strand
oligonucleotide, an EcoRI site at the 5' end of the antisense
strand oligonucleotide, and six additional nucleotides at the 5'
end of each oligonucleotide for stability and recutting effi-
ciency. The amplified fragment was subcloned into pGEX2T
in frame at both ends. The remaining GST fusion constructs
represent potential binding sites and were constructed by using
complementary oligonucleotides containing coding sequences
withBamHI and EcoRI sites at the 5' and 3' ends, respectively,
with five additional nucleotides at each end for cutting effi-
ciency. Complementary oligonucleotides were annealed by
boiling for 2 min and then cooling slowly to room temperature.
The DNA fragments were digested with BamHI and EcoRI
restriction enzymes and cloned into pGEX2T. The Btk binding
site was cloned as described (17).
Abbreviations: SH3, Src homology 3; GST, glutathione S-transferase.
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Sequencing of the library clones and the GST fusion con-
structs was carried out with the Sequenase kit (United States
Biochemical).
Biotinylated Proteins. The c-Abl, c-Src, n-Src, and v-Crk
GST-SH3 fusion proteins were prepared as described (8).
Cloning of the GST-SH3 fusion proteins for Fyn, Lyn, and Hck
has been described (17). Biotinylation of the SH3 domains was
performed as described (18).
RESULTS
Phage plaques expressing members of an embryonic mouse
cDNA library were screened with a mixed, biotinylated SH3
probe and partial cDNA clones expressing peptides that bound
to SH3 domains were isolated. All of the clones derived from
proteins with no counterpart in the GenBank data base
(November 1994). Total bacterial lysates expressing the iso-
lated clones as phage T7 gene 10 fusion proteins were frac-
tionated by electrophoresis, transferred to filter paper, and
probed with individual biotinylated SH3 domains (Fig. 1). Two
clones, 2b (and the identical 9c) and 9h, bound to all the SH3
domains tested, whereas clone lOa interacted with only c-Src
and n-Src SH3 domains. Clones lOb, lOg, and 101 exhibited
binding affinity for only the Abl SH3. Clone lOc and GST alone
did not bind to any of the SH3 domains tested. Certain of the
clones were examined further.
To determine how specificity of interaction is achieved, we
first examined the interaction of clone lOa with the Src SH3.
GST fusions of lOa subfragments were generated (Fig. 2A) and
tested by filter binding. An 18-aa peptide (peptide 2) bound the
SH3 (Fig. 2B). An N-terminal arginine was indispensable for
binding, since deletion of this arginine (peptide 1) or substi-
tution of a lysine for this arginine (peptide 3), abolished or
greatly reduced the binding affinity of this peptide (Fig. ZB).
The first 7 aa of peptide 2 (peptide 4) had the full binding
affinity of the longer peptide. This binding was quite strong-a
previously reported binding site for the Src SH3 on the p85a
subunit (peptide 5) showed very little binding when compared
with the RPLPALP sequence of lOa (Fig. ZB). An extended
construct that contained the C-terminal half of this peptide
and 2 aa immediately downstream (peptide 6) showed in-
creased binding when compared with peptide 5, but the
binding was still lower than with peptide 4. We then searched
the database for other proteins that contained the RPLPALP
motif. Two other proteins, a K+ channel and the calcitonin
receptor, contained sequences (peptides 7 and 8, respectively)
that closely matched the Src SH3 binding site on lOa. When
these were tested in filter binding assays they exhibited high
binding affinity for the Src SH3 that matched that of lOa. The
binding activity of the lOa peptide was compared with that of
peptides from a biased combinatorial peptide library recently
shown to bind to the Src SH3 with high affinity (14). Fragment
lOa was tested against peptides 9 and 10 and exhibited binding
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FIG. 2. A peptide fragment with the consensus sequence
RPLPXXP binds to SH3 domains of Src and Src-related kinases. (A)
Sequences of peptides that were screened. Peptides 1-4 were derived
from the 10a protein fragment. Peptides 5 and 6 were from the p85a
subunit of phosphatidylinositol 3-kinase. Peptides 7 and 8 were from
proteins identified in the GenBank database. Peptides 9 and 10 were
high-affinity Src SH3-binding peptides defined in a peptide library
screen by Yu et at (14). (B) Complementary oligonucleotides encoding
the 10 peptides were cloned into pGEX2T and were expressed as GST
fusion proteins. Blot transfers of electrophoretically fractionated
bacterial lysates were probed with biotinylated Src SH3. (C) Blot
transfers of bacteria lysates expressing GST fusion peptides 2-6 were
probed with various SH3 domains as shown. (D) Blot transfers of GST
fusions of KKPLPPTPEE (lane 1) and KKPLPPEPTA (lane 2)-
high- and low-affinity sites, respectively, present on Btk-and a 92-aa
fragment of 10a (lane 3) were probed with SH3 domains from Src and
Src-related kinases. Biotinylated GST and antibodies to GST (a-GST)
were included as controls.
constants of 7.8 and 9.6 ,uM, respectively. The binding of lOa
to the Src SH3 was at least as good, if not slightly better, that
of peptides 9 and 10, suggesting that lOa does indeed bind to
the Src SH3 with high affinity as compared with published
data.
Peptides 2-6 bound to the SH3 domains of the Src-related
kinases Fyn, Lyn, and Hck with the same affinity as to the Src
SH3 (Fig. 2C). This is not surprising, since the three-
dimensional structures of these SH3 domains overlap closely.
However, differences in binding to proline-rich sequences do
exist between the members of the Src kinase family. It has been
shown recently that the Fyn, Lyn, and Hck SH3 domains, but
not the Src SH3, bind to Btk (Bruton tyrosine kinase) through
a KKPLPPTPEE motif (17). This fulfills the requirements of
the RPLPXXP motif except for the R -> K substitution. We
therefore compared the affinities of the Src SH3 and Src-
related SH3 domains for the Btk and lOa binding sites. As
predicted, all the SH3 domains bound to GST-lOa, whereas
only Fyn, Lyn, and Hck SH3 domains bound to the Btk site
(Fig. 2D). The affinity of the SH3 domains for GST-lOa was
higher than that for Btk, since stronger binding was observed
'Q
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FIG. 1. Determination of peptide binding specificities. Bacteria were transformed with pEXlox expressing fusion proteins made by linkage of
gene 10 of phage T7 (Materials and Methods) and cDNAs cloned into an EcoRI-HindIII site of pEXlox. Expression of fusion proteins was induced
with 0.1 mM isopropyl f3-D-thiogalactopyranoside for 2 hr. Identical blotted transfers of bacterial lysates were probed with biotinylated GST-SH3
fusion proteins or with GST as indicated. The blots were developed with streptavidin-conjugated alkaline phosphatase.
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with 10a when approximately equal amounts of protein were
loaded (a-GST blot, Fig. 2D).
Clone 9h was one that bound to both Src and Abl SH3
domains; we examined it further because it had no apparent
RPLPXXP motif for binding to the Src SH3. We could localize
the binding sites for both SH3 domains to peptide 9h-3, a
proline-rich region of sequence PPPPPPPLPPR (Table 1). The
C-terminal arginine was essential for binding to SH3 domains,
as were at least some of the five N-terminal prolines (compare
9h-derived peptides in Table 1). The data above, as well as the
work of others (14, 16), suggest that a Src SH3-binding site
needs an N-terminal arginine, but that is lacking in 9h-3. This
puzzle is explained by recent evidence that the SH3 domains
of Src and phosphatidylinositol 3-kinase select for two classes
of ligands from a biased random peptide library (14) (15) that
bind in opposite orientations to the SH3: class I ligands,
containing RPLPPXP motif, and class II ligands, containing
the consensus XXXPPLPXR (15). From these data we can
conclude that clone 10a is a class I ligand whereas 9h is a class
II ligand and that the two bind to the Src SH3 in opposite
orientations. It is perhaps significant that 9h binds to the Abl
SH3 as well as to the Src SH3, whereas 10a is specific for
Src-family SH3 domains. This suggests that peptides binding in
the class I orientation may be more specific than those binding
in the class II orientation.
A third clone, 2b, that also exhibited broad binding speci-
ficity was mapped for sites that interacted with different SH3
domains. Two proline-rich sites were evident by inspection
(2b-1 and 2b-5, Table 1). Peptide 2b-1 bound to both the Abl
and the Src SH3 with high affinity, whereas 2b-5 interacted
only weakly. A Src SH3 site, RPLPPPP, was immediately
apparent-in 2b-1. Peptide 2b-5, which did not bind to the Src
SH3, contained a closely related sequence, RAPPPPP, show-
ing that leucine at position 3 is important for ligand binding to
the Src SH3. Binding to the Abl SH3 seemed more complex.
Because 2b-3 did not bind, but 2b-2 and -4 bound well (Table
1), it appears that binding to the Abl SH3 is mediated by either
of two overlapping sites. These sites (as well as 9h-3 and
segments of lOg and 101 in Fig. 1) fulfilled the previously
suggested requirements for Abl SH3 binding-namely, pro-
lines at positions 2, 7, and 10 (see Table 2) (9, 19). Thus
proteins can contain sequences that bind to more than one SH3
domain by using different subsites.
Our data and those of others (14-16) imply that SH3
domains from Abl and Src (and Src-related kinases) recognize
ligands with different consensus sequences. A recent report,
however, suggests that short peptides from proteins 3BP1 and
3BP2, previously identified as prototypical Abl SH3 ligands,
bind the to the Abl and Fyn SH3 domains with the same
affinity (Kd of 34 ,uM) (19). These peptides lack basic amino
acids (see top lines in Table 2) and should be unable to bind
Abl-SH3 Src-SH3 Fyn-SH3 GST
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FIG. 3. Differential binding of peptide ligands to the Abl, Src, and
Fyn SH3 domains. Western blots of lysates are shown of GST fusion
peptides of the Abl SH3 ligands 3BP1-10 (9), 3BP2-12 (9), and lOg
(lanes 1-3), the Src SH3 ligand 10a (lanes 4) (peptide 2, Fig. 2A), and
9h-3 and 2b-1 (lanes 5 and 6). Sequences are given in Table 2.
to the Src-like Fyn SH3 domain. Therefore, the different sites
were tested in parallel for binding to SH3 domains from Abl,
Src, and Fyn (Fig. 3). Under the conditions used, we could not
detect binding of the Src, and Fyn SH3 domains to 3BP1, 3BP2,
and 10g, all of which specifically recognize the Abl SH3 (Fig.
3, lanes 1-3). In the same experiments 9h and 2b exhibited
binding to all SH3 domains tested, as expected (Fig. 3, lanes 5
and 6), whereas 10a was recognized only by SH3 domains from
Src and related kinases (Fig. 3, lanes 4). The differences
between our data and those of Musacchio et at (19) may be due
to the different experimental conditions used for these exper-
iments, although our filter binding assay data correlate well
with the structural studies published by Yu et at (14).
DISCUSSION
We have identified and characterized peptide ligands on
unidentified cellular proteins that are binding sites for the Abl,
Src, and Src-related SH3 domains. The rules for binding
specificity and affinity that emerge from investigating these
ligands are similar to those implied from studies of artificial
peptide ligands. Binding is mediated through proline-rich sites
that share common elements but also have residues that
contribute to specificity.
Combining the data from this study with data from other
studies, we can distinguish four types of SH3 binding sites
(Table 2). All require a PXXP motif, but then they differ. The
first difference is the class I/class II distinction, which deter-
mines the N-terminal to C-terminal ligand binding orientation.
Among the class I sites are those specific for Src and those
specific for Abl. The sites for Abl SH3 binding are about 10 aa
long and conserve three prolines, those at positions 7 and 10,
which are in the PXXP sequence, and another at position 2.
Abl SH3 binding sites do not necessarily have any basic amino
acids. The Src SH3 ligands are 7 aa long and have an arginine at
position 1 and the PXXP from 4 to 7. Src-related kinases have
SH3 domains that bind to the Src peptide but also, although less
well, to peptides with a lysine in the place of the arginine.
Table 1. Identification of Src and Abl SH3 binding sites on clones 9h and 2b
Peptide Sequence Src SH3 Abl SH3
9h-0 AARAGQLEPQLRAPAHSSPLPPPPPPPPPPPLPPRGAARSSPRSRSR ++++ +++
9h-1 AARAGQLEPQLRAPAHSSPLPPPPPPPPPPPLPP
--/+
9h-2 PPLPPRGAARSSPRSPSR ++ +
9h-3 PPPPPPPLPPR ++++ +++
2b-O RLGAPDSRPPARPLPPPPPAPRPPRCRRRLRFLRGGLRPSRRRLRAPPPPPPSTM ++++ ++++
2b-1 PPARPLPPPPPAPRPPR ++++ ++++
2b-2 PPARPLPPPPPA ++++ +++
2b-3 ARPLPPPPPA ++++-
2b-4 ARPLPPPPPAPRPPR ++++ +++
2b-5 RPSRRRLRAPPPPPPST - +
Peptide 9h-0 is a segment of clone 9h that retains full binding to Src and Abl SH3 domains. Peptides 9h-1, -2, and -3 are
deletion peptides of 9h-0. Peptide 2b-0 is a segment of clone 2b that retains full binding affinity for Src and Abl SH3 domains.
Peptides 2b-1 to -5 are deletion peptides of 2b that define overlapping yet distinct Src and Abl SH3 binding sites. Blot transfers
of bacterial lysates expressing the peptides as GST fusion proteins were probed with Src and Abl SH3 proteins. The relative binding
of the peptides was graded from very strong (+ + + +) to not detectable (-).
Proc. Natl. Acad ScL USA 92 (1995)
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Table 2. Alignments of binding sites for various SH3 domains








Src, Fyn, Lyn, Hck lOa RPLHALP
p85a RIPLIPEVAIP
2b R PLEPPPP
Fyn, Lyn, Hck BTK1 KPLPPTP
Class II
Abl, Src, Fyn, Crk, Src+* 9h PPPPPPPLPEPR
Grb-2 Sos PVPIEIP V1PIPRRR
Crk, Grb-2 AB3-1 APEELIPETKTR
Crk AB3-2 EPAVSIPELLPRKER
Grb-2, Nck AB3-3 MA EPTPPEKR
Amino acids that are important for binding within each group of
ligands are boxed.
*n-Src indicates neuronal Src.
The class II ligands are often sites for SH3 domains of
adapter proteins such as Crk (20) and Grb-2 (21-24) and have
the general form XPXXPXR (15). Sequence alignments of Crk
SH3 binding sites on c-Abl (20) and the Sos site that binds to
Grb-2 indicate that lysine can substitute for arginine at the C
terminus of Crk-SH3 ligands (Table 2). The Grb-2 site on Sos
contains three arginine residues at the C terminus, all ofwhich
are required for high-affinity binding to Grb-2 SH3 domains
(15). Extended peptides for the Crk SH3 contain additional
arginine residues that may be important for binding (unpub-
lished results). Therefore, more flexibility in the distance
between the PXXP and the arginine may exist in class II
ligands. That flexibility, as well as the presence of arginine or
lysine at the C terminus, may be a source of specificity, since
many of the class II sites are specific for one or another of the
adapter proteins (20).
The structures of many SH3 domains with bound peptides
are known at atomic resolution (25-31). From these structures,
the binding rules can be rationalized. SH3 domains have an
extended hydrophobic patch that binds the proline-containing
ligands into two pockets, sites 1 and 2. In either orientation, the
prolines bond with aromatic and proline residues. The arginine
residue, which is a key feature of most ligands, fits into site 3,
where it is anchored by interaction with acidic resides at the
base of the site. The Src SH3 has only one acidic residue
(position 99), whereas the Fyn, Lyn, and Hck SH3 domains
have two (positions 98 and 99), perhaps explaining the ability
of the latter to bind ligands where lysine has replaced arginine.
Only the Abl SH3 lacks any acidic residue in this region, and
the Abl SH3 binds to a ligand that lacks an arginine. The Abl
SH3 ligand is longer and has a key proline near its N-terminal
end that binds in the hydrophobic pocket adjacent to site 3.
Being longer than the Src SH3 sites, it makes a 2-aa turn before
binding back to the SH3. The class II ligands all contain a
C-terminal arginine that can bind at site 3. Because they bind
in opposite orientation from the class I ligands they are
formally equivalent to the Src sites, although the presence of
multiple basic residues on the C terminus suggests that more
flexibility in the distance between the PXXP and the arginine
may exist. This distance may correlate with specificity of
binding, although no mutagenic studies of the role of that
distance in binding specificity have been reported.
One apparent contradiction to this picture of SH3 specificity
is that Musacchio et at (19) found that an Abl SH3 ligand (the
3BP2 peptide) bound as well to the Fyn SH3 in spite of not
having an arginine. From their crystal structure, it is evident
that the Fyn SH3 binding can take place and that it is like the
binding of the ligand to the Abl SH3 in that the site adjacent
to site 3 is used to bind a proline residue. However, we found
that the binding to the Fyn SH3 was so weak that it was not
detectable by our assay, and therefore this is unlikely to be a
physiological mode of binding.
Class II peptides seem more promiscuous in their binding
than class I ligands. For instance, fragment 9h exhibited
binding to Abl, Src, n-Src, Crk, and Fyn SH3 domains (Table
2). This may be a consequence of the flexibility in the distance
from the PXXP to the arginine. It is important to note that 9h
ends with the sequence PPPPLPPR, in which PXXP can be in
either of two positions, and it could bind in one way to some
SH3 domains and in another to others. This we found was the
interpretation of the binding of fragment 2b to both the Src and
the Abl SH3 domains.
In this work we have focused only on the binding of short
peptides, but we have occasionally noted that longer peptides
bind more strongly than short ones (unpublished results). This
suggests that in real protein ligands, there may be SH3 contacts
from more than one region of the protein. In one case-the
binding of Hck SH3 to the human immunodeficiency virus Nef
protein-we have developed direct evidence for interactions
from two widely spaced sites on Nef (32). Because the extent
of specificity evident in our studies is still quite crude, we
believe that another level of specificity, perhaps deriving from
multiple interactions with SH3, explains finer distinctions. In
fact, the interaction with Nef occurs well with the Hck SH3 but
poorly with the Fyn SH3, indicating that a complex ligand can
make distinctions not evident when peptides are studied.
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